{"groups":[{"description":"Phase 1, Level 1: Ruxolitinib 5 mg twice daily","id":"FG000","title":"Phase 1, Level 1: Ruxolitinib 10 mg"},{"description":"Phase 1 Level 2: Ruxolitinib 10 mg twice daily","id":"FG001","title":"Phase 1 Level 2: Ruxolitinib 20 mg"},{"description":"Phase 1 Level 3: Ruxolitinib 15 mg twice daily","id":"FG002","title":"Phase 1 Level 3: Ruxolitinib 30 mg"},{"description":"Phase 1 Level 4: 20 mg Ruxolitinib twice daily","id":"FG003","title":"Phase 1 Level 4: 40 mg Ruxolitinib"},{"description":"Phase II: Treatment at Maximum Tolerated Dose (MTD).","id":"FG004","title":"Phase 2: Maximum Tolerated Dose - Ruxolitinib"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"30"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}